Table 2.
Clinicopathological characteristics of the study participants (N = 555)
| Characteristics | N(%) |
|---|---|
| Age yr, median (range) | 54 (26–87) |
| Estrogen Receptor | |
| Negative | 202 (36.4) |
| Positive | 353 (63.6) |
| Progesterone Receptor | |
| Negative | 297 (53.5) |
| Positive | 258 (46.5) |
| Ki-67 | |
| ≤ 20 | 103 (18.6) |
| > 20 | 389 (70.1) |
| unknown | 63 (11.3) |
| Grading | |
| G1 | 6 (1.1) |
| G2 | 148 (26.7) |
| G3 | 339 (61.1) |
| unknown | 62 (11.2) |
| Immunohistochemical Subtype | |
| TP | 244 (44.0) |
| ER or PgR positive | 109 (19.6) |
| ER and PgR negative | 202 (36.4) |
| Metastatic at Diagnosis | |
| No | 398 (71.7) |
| Yes | 157 (28.3) |
| Neo−/adjuvant treatmenta | |
| Yes | 363 (91.2) |
| No | 35 (8.8) |
| Neo−/adjuvant trastuzumaba | |
| Yes | 212 (53.3) |
| No | 186 (46.7) |
| Metastatic Sites | |
| Visceral | 397 (71.5) |
| Bone-Only | 25 (4.5) |
| Brain | 155 (27.9) |
| Number of Metastatic Sites | |
| 1 | 397 (71.5) |
| 2 | 85 (15.3) |
| > 2 | 73 (13.2) |
| Disease Free Interval in months, median | |
| No first-line Pertuzumab / T-DM1 in second-line | 40 |
| No first-line Pertuzumab / T-DM1 subsequent lines | 53 |
| First-line Pertuzumab / T-DM1 in second-line | 47 |
| No first-line Pertuzumab / T-DM1 in subsequent lines | 28 |
| T-DM1 in first-line | 17 |
| T-DM1 treatment line | |
| First-line | 25 (4.5) |
| Second-line | 371 (66.8%) |
| Third-line | 96 (17.3%) |
| Subsequent lines | 63 (11.4%) |
aFor patients with early disease at diagnosis (398 patients)
Abbreviations: N Number; yr Years; TP Triple positive; ER Estrogen receptor; PgR Progesterone receptor